FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W110791873> ?p ?o ?g. }

• W110791873 endingPage "381" @default.
• W110791873 startingPage "377" @default.
• W110791873 abstract "Decision-analytic cost-effectiveness models are used to determine the most cost-effective treatment option on the basis of the best available data. Guidelines for pharmacoeconomic model development indicate that models should be updated as new evidence becomes available.To evaluate the appropriateness of the clinical data that were selected for Goldberg et al.'s 2009 model of cost-effectiveness in multiple sclerosis and calculate results based on a revised cohort selection method for intramuscular (IM) interferon (IFN) beta-1a.The original model compared cost per relapse avoided for IM IFN beta-1a, subcutaneous (SC) IFN beta-1a, IFN beta-1b, and glatiramer acetate (GA) based on intent-to-treat (ITT) results from clinical trials. However, due to lower-than-expected subject dropout rates, the IM IFN beta-1a trial had sufficient statistical power to be terminated early and was subsequently found to have met its primary endpoint, time to sustained 1.0-point Expanded Disability Status Scale progression. Within the all-patient(ITT) cohort (n=301), approximately 43% of patients were followed for less than 2 years; 172 patients were followed for 2 years or more. In contrast, the proportions of patients followed for at least 2 years in the clinical trials of IFN beta-1b, SC IFN beta-1a, and GA were 92%, 90%, and 86%, respectively. To test the impact of data selection on the cost-effectiveness model results, we recreated the original model using both the all-patient and 2-year cohorts from the IM IFN beta-1a pivotal trial. We then compared our results with those of the original model.In the original model, costs per relapse avoided were $141,721 for IM IFN beta-1a, $80,589 for SC IFN beta-1a, $87,061 for SC IFN beta-1b, and $88,310 for GA. In the reanalysis using the 2-year completer data for IM IFN beta-1a, costs per relapse avoided were $77,980 for IM IFN beta-1a, $80,121 for SC IFN beta-1a, $86,572 for IFN beta-1b, and $87,767 for GA. The cost per relapse avoided for IM IFN beta-1a was approximately 45% lower than in the original analysis, whereas the recreated results for the other 3 therapies differed from the original results by less than 1%. Sensitivity analyses showed that the recreated model was robust and that the rank order of cost-effectiveness results was unaffected by changes to any univariate parameter.The current study highlights the importance of data selection in cost-effectiveness analyses. After limiting the pivotal trial data for IM IFN beta-1a to patients followed for at least 2 years, we found that IM IFN beta-1a was more cost-effective than in the original analysis, while results for the other first-line disease-modifying drugs remained stable." @default.
• W110791873 created "2016-06-24" @default.
• W110791873 creator A5043925265 @default.
• W110791873 creator A5071073668 @default.
• W110791873 date "2011-06-01" @default.
• W110791873 modified "2023-09-25" @default.
• W110791873 title "Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis" @default.
• W110791873 cites W1943280741 @default.
• W110791873 cites W1997577436 @default.
• W110791873 cites W2001446148 @default.
• W110791873 cites W2005506388 @default.
• W110791873 cites W2046655585 @default.
• W110791873 cites W2053199643 @default.
• W110791873 cites W2060513754 @default.
• W110791873 cites W2061005334 @default.
• W110791873 cites W2076814339 @default.
• W110791873 cites W2112270506 @default.
• W110791873 cites W2130779793 @default.
• W110791873 cites W2134015462 @default.
• W110791873 cites W2139367012 @default.
• W110791873 cites W2161906602 @default.
• W110791873 cites W2188468660 @default.
• W110791873 cites W2308703407 @default.
• W110791873 doi "https://doi.org/10.18553/jmcp.2011.17.5.377" @default.
• W110791873 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21657808" @default.
• W110791873 hasPublicationYear "2011" @default.
• W110791873 type Work @default.
• W110791873 sameAs 110791873 @default.
• W110791873 citedByCount "19" @default.
• W110791873 countsByYear W1107918732012 @default.
• W110791873 countsByYear W1107918732013 @default.
• W110791873 countsByYear W1107918732014 @default.
• W110791873 countsByYear W1107918732015 @default.
• W110791873 countsByYear W1107918732017 @default.
• W110791873 countsByYear W1107918732019 @default.
• W110791873 countsByYear W1107918732020 @default.
• W110791873 countsByYear W1107918732021 @default.
• W110791873 crossrefType "journal-article" @default.
• W110791873 hasAuthorship W110791873A5043925265 @default.
• W110791873 hasAuthorship W110791873A5071073668 @default.
• W110791873 hasBestOaLocation W1107918732 @default.
• W110791873 hasConcept C112930515 @default.
• W110791873 hasConcept C126322002 @default.
• W110791873 hasConcept C1862650 @default.
• W110791873 hasConcept C203014093 @default.
• W110791873 hasConcept C203092338 @default.
• W110791873 hasConcept C2778577042 @default.
• W110791873 hasConcept C2779134260 @default.
• W110791873 hasConcept C2780640218 @default.
• W110791873 hasConcept C2908698914 @default.
• W110791873 hasConcept C2994247566 @default.
• W110791873 hasConcept C3019080777 @default.
• W110791873 hasConcept C535046627 @default.
• W110791873 hasConcept C71924100 @default.
• W110791873 hasConcept C72563966 @default.
• W110791873 hasConceptScore W110791873C112930515 @default.
• W110791873 hasConceptScore W110791873C126322002 @default.
• W110791873 hasConceptScore W110791873C1862650 @default.
• W110791873 hasConceptScore W110791873C203014093 @default.
• W110791873 hasConceptScore W110791873C203092338 @default.
• W110791873 hasConceptScore W110791873C2778577042 @default.
• W110791873 hasConceptScore W110791873C2779134260 @default.
• W110791873 hasConceptScore W110791873C2780640218 @default.
• W110791873 hasConceptScore W110791873C2908698914 @default.
• W110791873 hasConceptScore W110791873C2994247566 @default.
• W110791873 hasConceptScore W110791873C3019080777 @default.
• W110791873 hasConceptScore W110791873C535046627 @default.
• W110791873 hasConceptScore W110791873C71924100 @default.
• W110791873 hasConceptScore W110791873C72563966 @default.
• W110791873 hasIssue "5" @default.
• W110791873 hasLocation W1107918731 @default.
• W110791873 hasLocation W1107918732 @default.
• W110791873 hasLocation W1107918733 @default.
• W110791873 hasOpenAccess W110791873 @default.
• W110791873 hasPrimaryLocation W1107918731 @default.
• W110791873 hasRelatedWork W1983662281 @default.
• W110791873 hasRelatedWork W2000443242 @default.
• W110791873 hasRelatedWork W2004358167 @default.
• W110791873 hasRelatedWork W2400764171 @default.
• W110791873 hasRelatedWork W2406066426 @default.
• W110791873 hasRelatedWork W2419206582 @default.
• W110791873 hasRelatedWork W2504156208 @default.
• W110791873 hasRelatedWork W2809359419 @default.
• W110791873 hasRelatedWork W3155971544 @default.
• W110791873 hasRelatedWork W2909629253 @default.
• W110791873 hasVolume "17" @default.
• W110791873 isParatext "false" @default.
• W110791873 isRetracted "false" @default.
• W110791873 magId "110791873" @default.
• W110791873 workType "article" @default.